Omnicell (OMCL) 10-Q9 May 222022 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2022	Apr. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-33043
Entity Registrant Name	OMNICELL, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3166458
Entity Address, Address Line One	590 East Middlefield Road
Entity Address, City or Town	Mountain View
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94043
City Area Code	650
Local Phone Number	251-6100
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	OMCL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		44,198,195
Entity Central Index Key	0000926326
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 265,008	$ 349,051
Accounts receivable and unbilled receivables, net of allowances of $5,278 and $5,272, respectively	290,469	240,894
Inventories	137,056	119,924
Prepaid expenses	24,228	22,499
Other current assets	58,843	48,334
Total current assets	775,604	780,702
Property and equipment, net	77,062	71,141
Long-term investment in sales-type leases, net	19,051	18,391
Operating lease right-of-use assets	43,204	48,549
Goodwill	740,426	738,900
Intangible assets, net	269,427	277,616
Long-term deferred tax assets	16,054	15,883
Prepaid commissions	59,643	63,795
Other long-term assets	122,117	127,519
Total assets	2,122,588	2,142,496
Current liabilities:
Accounts payable	71,645	71,513
Accrued compensation	47,271	71,130
Accrued liabilities	139,829	133,167
Deferred revenues, net	127,998	112,196
Convertible senior notes, net	564,269	488,152
Total current liabilities	951,012	876,158
Long-term deferred revenues	24,037	20,194
Long-term deferred tax liabilities	28,173	51,705
Long-term operating lease liabilities	37,273	39,911
Other long-term liabilities	7,352	7,839
Total liabilities	1,047,847	995,807
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 54,457 and 54,073 shares issued; 44,174 and 44,179 shares outstanding, respectively	54	54
Treasury stock at cost, 10,283 and 9,894 shares outstanding, respectively	(290,319)	(238,109)
Additional paid-in capital	982,675	1,024,580
Retained earnings	393,293	368,571
Accumulated other comprehensive loss	(10,962)	(8,407)
Total stockholders’ equity	1,074,741	1,146,689
Total liabilities and stockholders’ equity	$ 2,122,588	$ 2,142,496

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for credit losses on accounts receivable and unbilled receivables	$ 5,278	$ 5,272
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common Stock, shares issued (in shares)	54,457,000	54,073,000
Common stock, shares outstanding (in shares)	44,174,000	44,179,000
Treasury stock, shares outstanding (in shares)	10,283,000	9,894,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues	$ 318,828	$ 251,843
Cost of revenues	168,781	129,560
Gross profit	150,047	122,283
Operating expenses:
Research and development	25,030	16,080
Selling, general, and administrative	119,933	86,593
Total operating expenses	144,963	102,673
Income from operations	5,084	19,610
Interest and other income (expense), net	(114)	(6,691)
Income before provision for income taxes	4,970	12,919
Benefit from income taxes	(3,243)	(1,208)
Net income	$ 8,213	$ 14,127
Net income per share:
Basic (in dollars per share)	$ 0.19	$ 0.33
Diluted (in dollars per share)	$ 0.17	$ 0.30
Weighted-average shares outstanding:
Basic (in shares)	44,249	42,962
Diluted (in shares)	47,918	46,367
Product revenues
Revenues	$ 225,875	$ 178,125
Cost of revenues	118,338	92,627
Services and other revenues
Revenues	92,953	73,718
Cost of revenues	$ 50,443	$ 36,933

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 8,213	$ 14,127
Other comprehensive loss:
Foreign currency translation adjustments	(2,555)	(621)
Other comprehensive loss	(2,555)	(621)
Comprehensive income	$ 5,658	$ 13,506

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Cumulative effect of a change in accounting principle related to convertible debt	Common Stock	Treasury Stock	Additional Paid-In Capital	Additional Paid-In CapitalCumulative effect of a change in accounting principle related to convertible debt	Accumulated Earnings	Accumulated EarningsCumulative effect of a change in accounting principle related to convertible debt	Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2020			52,677,000
Balance at beginning of period at Dec. 31, 2020	$ 967,503		$ 53	$ (238,109)	$ 920,359		$ 290,722		$ (5,522)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2020				(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	14,127						14,127
Other comprehensive income (loss)	(621)								(621)
Share-based compensation	11,772				11,772
Issuance of common stock under employee stock plans (in shares)			388,000
Issuance of common stock under employee stock plans	20,826				20,826
Tax payments related to restricted stock units	(2,596)				(2,596)
Balance at end of period (in shares) at Mar. 31, 2021			53,065,000
Balance at end of period at Mar. 31, 2021	1,011,011		$ 53	$ (238,109)	950,361		304,849		(6,143)
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2021				(9,894,000)
Balance at beginning of period (in shares) at Dec. 31, 2020			52,677,000
Balance at beginning of period at Dec. 31, 2020	$ 967,503		$ 53	$ (238,109)	920,359		290,722		(5,522)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2020				(9,894,000)
Balance at end of period (in shares) at Dec. 31, 2021	44,179,000		54,073,000
Balance at end of period at Dec. 31, 2021	$ 1,146,689	$ (56,233)	$ 54	$ (238,109)	1,024,580	$ (72,742)	368,571	$ 16,509	(8,407)
Balance at end of period, Treasury stock (in shares) at Dec. 31, 2021	(9,894,000)			(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Net income (loss)	$ 8,213						8,213
Other comprehensive income (loss)	(2,555)								(2,555)
Share-based compensation	16,208				16,208
Issuance of common stock under employee stock plans (in shares)			384,000
Issuance of common stock under employee stock plans	18,951				18,951
Tax payments related to restricted stock units	(4,322)				(4,322)
Stock repurchases (in shares)				(389,000)
Stock repurchases	$ (52,210)			$ (52,210)
Balance at end of period (in shares) at Mar. 31, 2022	44,174,000		54,457,000
Balance at end of period at Mar. 31, 2022	$ 1,074,741		$ 54	$ (290,319)	$ 982,675		$ 393,293		$ (10,962)
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2022	(10,283,000)			(10,283,000)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating Activities
Net income (loss)	$ 8,213	$ 14,127
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	21,124	17,575
Share-based compensation expense	16,208	11,772
Deferred income taxes	(4,858)	(862)
Amortization of operating lease right-of-use assets	3,307	2,895
Impairment of operating lease right-of-use assets	1,753	0
Amortization of debt issuance costs	1,038	849
Amortization of discount on convertible senior notes	0	4,571
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables	(49,994)	(15,427)
Inventories	(17,320)	(1,035)
Prepaid expenses	(1,712)	(1,095)
Other current assets	7,950	3,128
Investment in sales-type leases	(1,097)	925
Prepaid commissions	4,152	2,710
Other long-term assets	2,240	2,177
Accounts payable	312	10,368
Accrued compensation	(23,859)	(17,899)
Accrued liabilities	769	4,661
Deferred revenues	19,786	21,749
Operating lease liabilities	(3,521)	(3,142)
Other long-term liabilities	(487)	(632)
Net cash provided by (used in) operating activities	(15,996)	57,415
Investing Activities
Software development for external use	(3,852)	(8,043)
Purchases of property and equipment	(11,489)	(5,089)
Business acquisition, net of cash acquired	(3,392)	0
Net cash used in investing activities	(18,733)	(13,132)
Financing Activities
Proceeds from issuances under stock-based compensation plans	18,951	20,826
Employees’ taxes paid related to restricted stock units	(4,322)	(2,596)
Change in customer funds, net	5,462	(2,631)
Stock repurchases	(52,210)	0
Net cash provided by (used in) financing activities	(32,119)	15,599
Effect of exchange rate changes on cash and cash equivalents	(411)	(386)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(67,259)	59,496
Cash, cash equivalents, and restricted cash at beginning of period	355,620	489,920
Cash, cash equivalents, and restricted cash at end of period	288,361	549,416
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets:
Cash and cash equivalents	265,008	548,055
Restricted cash included in Other current assets	23,353	1,361
Cash, cash equivalents, and restricted cash at end of period	288,361	549,416
Supplemental disclosure of non-cash activities
Unpaid purchases of property and equipment	703	487
Transfers between inventory and property and equipment, net	$ 0	$ 1,269

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
Organization and Summary of Significant Accounting Policies	Mar. 31, 2022
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of March 31, 2022 and December 31, 2021, and the results of operations, comprehensive income, and cash flows for the three months ended March 31, 2022 and 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 25, 2022, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations, comprehensive income, and cash flows for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the year ending December 31, 2022, or for any future period. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On January 10, 2022, the Company completed its acquisition of Hub and Spoke Innovations Limited (“Hub and Spoke Innovations”). The Condensed Consolidated Financial Statements include the results of operations of this recently acquired company, commencing as of the acquisition date. The significant accounting policies of the acquired business have been aligned to conform to the accounting policies of Omnicell. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of March 31, 2022, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities. Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. Recently Adopted Authoritative Guidance In August 2020, the Financial Accounting Standards Board (“FASB“) issued Accounting Standards Update (“ASU“) 2020-06 Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) . The update simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU 2020-06 also requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method is no longer permitted for convertible instruments. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2022, using the modified retrospective method of transition. Upon adoption of ASU 2020-06, the previously separated equity component and associated debt issuance costs for the Company’s outstanding convertible senior notes were reclassified to the liability component, thereby eliminating the subsequent amortization of the debt discount as interest expense. In addition, the Company derecognized the deferred tax liability related to the equity component. In December 2021, the Company made an irrevocable election under the indenture to require the principal portion of the Company’s convertible senior notes to be settled in cash and any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion. Following the irrevocable election, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. The Company’s adoption of the update impacted the Condensed Consolidated Balance Sheets at the beginning of the period of adoption as follows: January 1, 2022 Pre-ASU 2020-06 Balances ASU 2020-06 Adoption Impact Post-ASU 2020-06 Balances (In thousands) Long-term deferred tax assets $ 15,883 $ (452) $ 15,431 Convertible senior notes, net 488,152 75,353 563,505 Long-term deferred tax liabilities 51,705 (19,572) 32,133 Additional paid-in capital 1,024,580 (72,742) 951,838 Retained earnings 368,571 16,509 385,080 Adoption of the update did not have an impact on the Company’s Condensed Consolidated Statements of Operations or Condensed Consolidated Statements of Cash Flows as of January 1, 2022. Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes. Recently Issued Authoritative Guidance In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The guidance will be applied prospectively to acquisitions occurring on or after the effective date. ASU 2021-08 will be effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company is currently evaluating the impact ASU 2021-08 will have on its Condensed Consolidated Financial Statements. No other recently issued and effective authoritative guidance is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

Business Combinations

Business Combinations	3 Months Ended
Business Combinations	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations The Company accounted for its acquisitions in accordance with ASC 805, Business Combinations . The tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the respective acquisition dates. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual or legal criterion or the separability criterion, each as set forth in the accounting guidance. The preliminary fair values reflect management’s best estimates based on information available at the respective acquisition dates and may change as additional information is received over the measurement period, which will end no later than one year from the respective acquisition date. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company’s Condensed Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. 2022 Acquisition Hub and Spoke Innovations On January 10, 2022, the Company completed the acquisition of all of the outstanding equity interests in Hub and Spoke Innovations, pursuant to the terms and conditions of the Share Purchase Agreement, dated January 10, 2022, by and among Omnicell Limited (a wholly-owned subsidiary of the Company), Hub and Spoke Innovations Limited, and certain beneficial stockholders specified therein for a base purchase price of £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date), prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The preliminary purchase price transferred for the transaction, net of cash acquired, was £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date). Of the purchase price transferred, £1.9 million (approximately $2.5 million based on the exchange rate in effect at the acquisition date) was allocated to goodwill; £0.8 million (approximately $1.1 million based on the exchange rate in effect at the acquisition date) was allocated to intangible assets, which included customer relationships; and the remainder was allocated to net assets acquired. The Hub and Spoke Innovations acquisition is expected to complement Omnicell’s total solution technology portfolio for retail pharmacy in the United Kingdom to help pharmacies improve workflows, offer patients 24/7 access to their medications and provide enhanced patient care. 2021 Acquisitions MarkeTouch Media On December 31, 2021, the Company completed the acquisition of all of the outstanding equity interests in MarkeTouch Media, LLC (“MarkeTouch Media”) pursuant to the terms and conditions of the Unit Purchase Agreement, dated December 31, 2021, by and among ateb, Inc. (a wholly-owned subsidiary of the Company), MarkeTouch Media, LLC, MarkeTouch Holdings, Inc., Toucan Enterprises, Inc., and certain beneficial stockholders specified therein for a base purchase price of $82.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The MarkeTouch Media acquisition adds mobile and web-based technology and patient engagement solutions, which is expected to expand the footprint of EnlivenHealth ® across the retail pharmacy sector, while enhancing potential growth opportunities in new market segments like specialty pharmacy and pharmacy benefits management. ReCept On December 29, 2021, the Company completed the acquisition of all outstanding equity securities of ReCept Holdings, Inc. (“ReCept”) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated December 1, 2021, by and among Omnicell, Inc., ReCept Holdings, Inc., Redfish Acquisition Corp, and the representative of the securityholders for a base purchase price of $100.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The addition of ReCept’s specialty pharmacy management services for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio in an effort to address the growing and complex specialty pharmacy market. FDS Amplicare On September 9, 2021, the Company completed the acquisition of all of the outstanding equity interests in RxInnovation, Inc., operating as FDS Amplicare (“FDS Amplicare”), pursuant to the terms and conditions of the Agreement and Plan of Merger, dated July 25, 2021, by and among RxInnovation Inc., Omnicell, Inc., Fleming Acquisition Corp., and the representative of the securityholders for a base purchase price of $177.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The FDS Amplicare ® acquisition adds a comprehensive and complementary suite of Software-as-a-Service (“SaaS”) financial management, analytics, and population health solutions to the Company’s EnlivenHealth offering. The following tables represent the preliminary allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred: FDS Amplicare (1) ReCept (Preliminary) (2) MarkeTouch Media (In thousands) Purchase price transferred: Base purchase price $ 177,000 $ 100,000 $ 82,000 Add: Closing cash 465 6,664 191 Add: Net working capital adjustment 1,654 (2,296) 448 Less: Assumed indebtedness (653) (1,902) (13) Total purchase price transferred $ 178,466 $ 102,466 $ 82,626 FDS Amplicare (Preliminary) (1) ReCept (Preliminary) (2) MarkeTouch Media Fair value of assets acquired and liabilities assumed: Cash and cash equivalents $ 465 $ — $ 237 Accounts receivable and unbilled receivables 5,330 2,383 2,302 Prepaid expenses 506 192 96 Other current assets 45 13,955 — Total current assets 6,346 16,530 2,635 Property and equipment 444 172 177 Operating lease right-of-use assets 2,252 773 602 Goodwill 117,374 81,588 42,530 Intangible assets 70,000 28,100 38,000 Other long-term assets 51 200 2,850 Total assets 196,467 127,363 86,794 Accounts payable 950 219 473 Accrued compensation 1,312 1,756 — Accrued liabilities 1,396 18,499 292 Deferred revenues 1,916 222 347 Long-term deferred tax liabilities 11,377 3,587 — Long-term operating lease liabilities 920 614 206 Other long-term liabilities 130 — 2,850 Total liabilities 18,001 24,897 4,168 Total purchase price $ 178,466 $ 102,466 $ 82,626 Total purchase price, net of cash acquired $ 178,001 $ 95,897 $ 82,389 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. (2) Closing cash is included in other current assets due to its restrictive nature as cash held for customers. The $117.4 million of goodwill arising from the FDS Amplicare acquisition is primarily attributed to future sales of SaaS solutions and FDS Amplicare’s assembled workforce. None of the FDS Amplicare goodwill is expected to be deductible for tax purposes. The $81.6 million of goodwill arising from the ReCept acquisition is primarily attributed to future sales of its offerings and services and ReCept’s assembled workforce. None of the ReCept goodwill is expected to be deductible for tax purposes. The $42.5 million of goodwill arising from the MarkeTouch Media acquisition is primarily attributed to future sales of SaaS solutions and MarkeTouch Media’s assembled workforce. The full amount of the MarkeTouch Media goodwill is expected to be deductible for tax purposes. The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: FDS Amplicare (1) ReCept MarkeTouch Media Fair value Useful life Fair value Useful life Fair value Useful life (In thousands, except for years) Customer relationships $ 59,900 23 $ 28,100 23 $ 34,100 26 Acquired technology 7,700 5 - 7 — — 2,100 4 Backlog — — — — 1,800 2 Trade names 2,400 5 — — — — Total purchased intangible assets $ 70,000 $ 28,100 $ 38,000 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships. The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions. The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization. Pro Forma Financial Information The following table presents certain unaudited pro forma consolidated financial information for the three months ended March 31, 2021 as if the FDS Amplicare, ReCept, and MarkeTouch Media acquisitions had been completed on January 1, 2020. The pro forma effects of the Hub and Spoke Innovations acquisition were not material to the Company’s consolidated results of operations. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the acquisitions taken place on those respective dates. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; and certain acquisition-related costs incurred. Three Months Ended March 31, 2021 (In thousands) Pro forma revenues $ 268,921 Pro forma net income $ 13,066

Revenues

Revenues	3 Months Ended
Revenues	Mar. 31, 2022
Revenue Recognition [Abstract]
Revenues	Revenues Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements with multi-year co-development plans. Solutions in this category include, but are not limited to, XT Series automated dispensing systems, the XR2 Automated Central Pharmacy System, and IV compounding automation solutions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, and are designed to improve patient engagement and adherence to prescriptions. SaaS, subscription software, and technology-enabled services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth inclusive of FDS Amplicare and MarkeTouch Media, 340B solutions, ReCept management services, and services associated with Omnicell One™, Central Pharmacy Dispensing Services, including the XR2 Automated Central Pharmacy System, and Central Pharmacy Compounding Services, including IV compounding automation solutions. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”) and Federal agencies that purchase under a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”). GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $4.5 million and $3.4 million for the three months ended March 31, 2022 and 2021, respectively. Disaggregation of Revenues The following table summarizes the Company’s revenues disaggregated by revenue type for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Connected devices, software licenses, and other $ 208,078 $ 159,718 Technical services 49,169 50,860 Consumables 17,797 18,407 SaaS, subscription software, and technology-enabled services 43,784 22,858 Total revenues $ 318,828 $ 251,843 The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) United States $ 287,577 $ 224,276 Rest of world (1) 31,251 27,567 Total revenues $ 318,828 $ 251,843 _________________________________________________ (1) No individual country represented more than 10% of total revenues. Contract Assets and Contract Liabilities The following table reflects the Company’s contract assets and contract liabilities: March 31, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 17,348 $ 17,208 Long-term unbilled receivables, net (2) 16,316 18,084 Total contract assets $ 33,664 $ 35,292 Short-term deferred revenues, net $ 127,998 $ 112,196 Long-term deferred revenues 24,037 20,194 Total contract liabilities $ 152,035 $ 132,390 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets. (2) Included in other long-term assets in the Condensed Consolidated Balance Sheets. The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues. Short-term deferred revenues of $128.0 million and $112.2 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $20.3 million and $22.4 million, as of March 31, 2022 and December 31, 2021, respectively. The short-term deferred revenues from product sales relate to delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. During the three months ended March 31, 2022, the Company recognized revenues of $66.6 million, that were included in the corresponding gross short-term deferred revenues balance of $134.6 million as of December 31, 2021. Long-term deferred revenues include deferred revenues from product and service contracts of $24.0 million and $20.2 million as of March 31, 2022 and December 31, 2021, respectively. Remaining performance obligations are primarily recognized ratably over the remaining term of the contract, generally not more than ten years. Significant Customers There were no customers that accounted for more than 10% of the Company’s total revenues for the three months ended March 31, 2022 and 2021. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of March 31, 2022 and December 31, 2021.

Net Income Per Share

Net Income Per Share	3 Months Ended
Net Income Per Share	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 10, Convertible Senior Notes (pre-ASU 2020-06 adoption). For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1 2022, the Company is required to apply the if-converted method for calculating the dilutive impact of the convertible senior notes. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share. The basic and diluted net income per share calculations for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended March 31, 2022 2021 (In thousands, except per share data) Net income $ 8,213 $ 14,127 Weighted-average shares outstanding – basic 44,249 42,962 Effect of dilutive securities from stock award plans 1,646 1,980 Effect of convertible senior notes 1,918 1,425 Effect of warrants 105 — Weighted-average shares outstanding – diluted 47,918 46,367 Net income per share – basic $ 0.19 $ 0.33 Net income per share – diluted $ 0.17 $ 0.30 Anti-dilutive weighted-average shares related to stock award plans 336 287 Anti-dilutive weighted-average shares related to convertible senior notes and warrants — 5,908

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $265.0 million and $349.1 million as of March 31, 2022 and December 31, 2021, respectively, consisted of bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with major financial institutions. As of March 31, 2022 and December 31, 2021, cash equivalents were $224.8 million and $320.2 million, respectively, which consisted of money market funds held in sweep and asset management accounts. Fair Value Hierarchy The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of March 31, 2022, the fair value of the convertible senior notes was $810.5 million, compared to their carrying value of $564.3 million, which is net of unamortized debt issuance costs. Refer to Note 9, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
Balance Sheet Components	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of March 31, 2022 and December 31, 2021 are presented in the tables below: March 31, December 31, (In thousands) Inventories: Raw materials $ 60,238 $ 48,215 Work in process 9,483 11,009 Finished goods 67,335 60,700 Total inventories $ 137,056 $ 119,924 Other current assets: Funds held for customers, including restricted cash (1) $ 38,426 $ 20,405 Net investment in sales-type leases, current portion 11,103 10,665 Prepaid income taxes 5,265 6,656 Other current assets 4,049 10,608 Total other current assets $ 58,843 $ 48,334 Other long-term assets: Capitalized software, net $ 94,108 $ 96,995 Unbilled receivables, net 16,316 18,084 Deferred debt issuance costs 2,882 3,156 Other long-term assets 8,811 9,284 Total other long-term assets $ 122,117 $ 127,519 Accrued liabilities: Operating lease liabilities, current portion $ 11,809 $ 12,947 Customer fund liabilities 38,426 31,727 Advance payments from customers 10,337 8,191 Rebate liabilities 40,344 44,644 Group purchasing organization fees 6,503 7,115 Taxes payable 5,487 3,771 Other accrued liabilities 26,923 24,772 Total accrued liabilities $ 139,829 $ 133,167 _________________________________________________ (1) Includes restricted cash of $23.4 million and $6.6 million as of March 31, 2022 and December 31, 2021, respectively. The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Beginning balance $ (8,407) $ (5,522) Other comprehensive loss (2,555) (621) Ending balance $ (10,962) $ (6,143)

Property and Equipment

Property and Equipment	3 Months Ended
Property and Equipment	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment The following table represents the property and equipment balances as of March 31, 2022 and December 31, 2021: March 31, December 31, (In thousands) Equipment $ 90,930 $ 89,272 Furniture and fixtures 7,432 7,580 Leasehold improvements 20,913 20,623 Software 67,795 60,856 Construction in progress 16,217 14,757 Property and equipment, gross 203,287 193,088 Accumulated depreciation and amortization (126,225) (121,947) Total property and equipment, net $ 77,062 $ 71,141 Depreciation and amortization expense of property and equipment was $5.3 million and $4.8 million for the three months ended March 31, 2022 and 2021, respectively. The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of March 31, 2022 and December 31, 2021: March 31, December 31, (In thousands) United States $ 72,803 $ 66,788 Rest of world (1) 4,259 4,353 Total property and equipment, net $ 77,062 $ 71,141 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
Goodwill and Intangible Assets	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: December 31, Additions (1) Foreign currency exchange rate fluctuations March 31, (In thousands) Goodwill $ 738,900 2,549 (1,023) $ 740,426 _________________________________________________ (1) Refer to Note 2, Business Combinations, for further information. Intangible Assets, Net The carrying amounts and useful lives of intangible assets as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 311,089 $ (83,571) $ (1,106) $ 226,412 4 - 30 Acquired technology 92,066 (55,492) — 36,574 4 - 20 Backlog 1,800 (225) — 1,575 2 Trade names 9,200 (5,848) — 3,352 5 - 12 Patents 2,430 (1,216) — 1,214 2 - 20 Non-compete agreements 600 (300) — 300 3 Total intangibles assets, net $ 417,185 $ (146,652) $ (1,106) $ 269,427 December 31, 2021 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 309,989 $ (78,093) $ (933) $ 230,963 10 - 30 Acquired technology 95,466 (55,859) 6 39,613 4 - 20 Backlog 1,800 — — 1,800 2 Trade names 9,200 (5,600) 14 3,614 5 - 12 Patents 2,462 (1,186) — 1,276 2 - 20 Non-compete agreements 600 (250) — 350 3 Total intangibles assets, net $ 419,517 $ (140,988) $ (913) $ 277,616 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to the write-off of certain fully amortized intangible assets, partially offset by additions of intangible assets in connection with the Hub and Spoke Innovations acquisition. Amortization expense of intangible assets was $9.1 million and $6.3 million for the three months ended March 31, 2022 and 2021, respectively. The estimated future amortization expenses for amortizable intangible assets were as follows: March 31, (In thousands) Remaining nine months of 2022 $ 26,204 2023 31,594 2024 23,139 2025 21,086 2026 18,099 Thereafter 149,305 Total $ 269,427

Debt and Credit Agreement

Debt and Credit Agreement	3 Months Ended
Debt and Credit Agreement	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt and Credit Agreement	Debt and Credit Agreement 2019 Revolving Credit Facility On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as subsequently amended as discussed below, the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The A&R Credit Agreement superseded the Company’s 2016 secured credit facility and provides for (a) a five-year revolving credit facility of $500.0 million (the “Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Incremental Facility”). In addition, the A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The A&R Credit Agreement has an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Revolving Credit Facility are subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Incremental Facility will be determined prior to the incurrence of such loans. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. On September 22, 2020, the parties entered into an amendment to the A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes , expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter. The A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. The Company’s obligations under the A&R Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The Company was in full compliance with all covenants as of March 31, 2022. As of each of March 31, 2022 and December 31, 2021, there was no outstanding balance for the Revolving Credit Facility. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended March 31, 2022, the conditional conversion feature of the Notes was triggered, based on the price of the Company’s common stock, as the last reported sale price of the Company’s common stock was greater than or equal to 130% of the then applicable conversion price for the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on March 31, 2022, the last trading day of the fiscal quarter. Accordingly, the Notes are convertible, in whole or in part, at the option of the holders during the second quarter of 2022. Whether the Notes will be convertible following the second fiscal quarter of 2022 will depend on the continued satisfaction of this condition or another conversion condition in the future. The Company continues to classify the Notes as a current liability in its Condensed Consolidated Financial Statements as of March 31, 2022 based on its irrevocable election to settle the principal amount in cash as discussed below. Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of March 31, 2022, none of the criteria for a fundamental change or a conversion rate adjustment had been met. The Company may not redeem the Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the Notes, at its option, on or after September 20, 2023, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. Prior to the adoption of ASU 2020-06, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. Accordingly, at issuance, the Company allocated $461.8 million to the debt liability and $72.7 million to additional paid-in capital, net of applicable issuance costs and deferred taxes. The difference between the principal amount of the Notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the Notes using an effective interest rate of 4.18%. The determination of the discount rate required certain estimates and assumptions. Upon adoption of ASU 2020-06, effective January 1, 2022, the Notes are no longer separated into liability and equity components, and are accounted for as a single liability measured at its amortized cost. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. As of March 31, 2022, the remaining life of the Notes and the related issuance cost accretion is approximately 3.5 years. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of March 31, 2022, the if-converted value of the Notes exceeded the principal amount by $190.1 million. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021: March 31, 2022 (2) December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount — (77,136) Unamortized debt issuance costs (10,731) (9,712) Convertible senior notes, liability component (1) $ 564,269 $ 488,152 Convertible senior notes, equity component $ — $ 72,732 _________________________________________________ (1) Classified as a current liability as of both March 31, 2022 and December 31, 2021 in the Condensed Consolidated Balance Sheets. (2) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 (1) 2021 (In thousands) Contractual coupon interest $ 359 $ 359 Amortization of discount $ — $ 4,571 Amortization of debt issuance costs $ 764 $ 575 _________________________________________________ (1) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
Convertible Senior Notes	Mar. 31, 2022
Debt Disclosure [Abstract]
Convertible Senior Notes	Debt and Credit Agreement 2019 Revolving Credit Facility On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as subsequently amended as discussed below, the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The A&R Credit Agreement superseded the Company’s 2016 secured credit facility and provides for (a) a five-year revolving credit facility of $500.0 million (the “Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Incremental Facility”). In addition, the A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The A&R Credit Agreement has an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Revolving Credit Facility are subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Incremental Facility will be determined prior to the incurrence of such loans. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. On September 22, 2020, the parties entered into an amendment to the A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes , expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter. The A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. The Company’s obligations under the A&R Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The Company was in full compliance with all covenants as of March 31, 2022. As of each of March 31, 2022 and December 31, 2021, there was no outstanding balance for the Revolving Credit Facility. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended March 31, 2022, the conditional conversion feature of the Notes was triggered, based on the price of the Company’s common stock, as the last reported sale price of the Company’s common stock was greater than or equal to 130% of the then applicable conversion price for the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on March 31, 2022, the last trading day of the fiscal quarter. Accordingly, the Notes are convertible, in whole or in part, at the option of the holders during the second quarter of 2022. Whether the Notes will be convertible following the second fiscal quarter of 2022 will depend on the continued satisfaction of this condition or another conversion condition in the future. The Company continues to classify the Notes as a current liability in its Condensed Consolidated Financial Statements as of March 31, 2022 based on its irrevocable election to settle the principal amount in cash as discussed below. Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of March 31, 2022, none of the criteria for a fundamental change or a conversion rate adjustment had been met. The Company may not redeem the Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the Notes, at its option, on or after September 20, 2023, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. Prior to the adoption of ASU 2020-06, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. Accordingly, at issuance, the Company allocated $461.8 million to the debt liability and $72.7 million to additional paid-in capital, net of applicable issuance costs and deferred taxes. The difference between the principal amount of the Notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the Notes using an effective interest rate of 4.18%. The determination of the discount rate required certain estimates and assumptions. Upon adoption of ASU 2020-06, effective January 1, 2022, the Notes are no longer separated into liability and equity components, and are accounted for as a single liability measured at its amortized cost. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. As of March 31, 2022, the remaining life of the Notes and the related issuance cost accretion is approximately 3.5 years. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of March 31, 2022, the if-converted value of the Notes exceeded the principal amount by $190.1 million. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021: March 31, 2022 (2) December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount — (77,136) Unamortized debt issuance costs (10,731) (9,712) Convertible senior notes, liability component (1) $ 564,269 $ 488,152 Convertible senior notes, equity component $ — $ 72,732 _________________________________________________ (1) Classified as a current liability as of both March 31, 2022 and December 31, 2021 in the Condensed Consolidated Balance Sheets. (2) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 (1) 2021 (In thousands) Contractual coupon interest $ 359 $ 359 Amortization of discount $ — $ 4,571 Amortization of debt issuance costs $ 764 $ 575 _________________________________________________ (1) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

Lessor Leases

Lessor Leases	3 Months Ended
Lessor Leases	Mar. 31, 2022
Leases [Abstract]
Lessor Leases	Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Sales-type lease revenues $ 6,505 $ 5,963 Cost of sales-type lease revenues (3,078) (2,366) Selling profit on sales-type lease revenues $ 3,427 $ 3,597 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2022 and December 31, 2021: March 31, December 31, (In thousands) Net minimum lease payments to be received $ 32,690 $ 31,444 Less: Unearned interest income portion (2,536) (2,388) Net investment in sales-type leases 30,154 29,056 Less: Current portion (1) (11,103) (10,665) Long-term investment in sales-type leases, net $ 19,051 $ 18,391 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2022 $ 9,024 2023 9,301 2024 6,300 2025 4,365 2026 1,972 Thereafter 1,728 Total future minimum sales-type lease payments 32,690 Present value adjustment (2,536) Total net investment in sales-type leases $ 30,154 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases . These agreements in place prior to January 1, 2019 continue to be treated as operating leases; however, any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Rental income $ 2,472 $ 2,611
Lessor Leases	Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Sales-type lease revenues $ 6,505 $ 5,963 Cost of sales-type lease revenues (3,078) (2,366) Selling profit on sales-type lease revenues $ 3,427 $ 3,597 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2022 and December 31, 2021: March 31, December 31, (In thousands) Net minimum lease payments to be received $ 32,690 $ 31,444 Less: Unearned interest income portion (2,536) (2,388) Net investment in sales-type leases 30,154 29,056 Less: Current portion (1) (11,103) (10,665) Long-term investment in sales-type leases, net $ 19,051 $ 18,391 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2022 $ 9,024 2023 9,301 2024 6,300 2025 4,365 2026 1,972 Thereafter 1,728 Total future minimum sales-type lease payments 32,690 Present value adjustment (2,536) Total net investment in sales-type leases $ 30,154 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases . These agreements in place prior to January 1, 2019 continue to be treated as operating leases; however, any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Rental income $ 2,472 $ 2,611

Lessee Leases

Lessee Leases	3 Months Ended
Lessee Leases	Mar. 31, 2022
Leases [Abstract]
Lessee Leases	Lessee Leases The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2022 $ 11,244 2023 11,459 2024 9,859 2025 6,909 2026 6,457 Thereafter 10,882 Total operating lease payments 56,810 Present value adjustment (7,728) Total operating lease liabilities (1) $ 49,082 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $11.8 million and $37.3 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities Operating lease costs were $4.1 million and $3.7 million for the three months ended March 31, 2022 and 2021, respectively. Short-term lease costs and variable lease costs were immaterial for the three months ended March 31, 2022 and 2021. During the three months ended March 31, 2022, the Company recorded an impairment of operating lease right-of-use assets of $1.8 million in connection with restructuring activities for optimization of certain leased facilities. The impairment charge was recorded to selling, general, and administrative expenses on the Company’s Condensed Consolidated Statements of Operations. The following table summarizes supplemental cash flow information related to the Company’s operating leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 4,193 $ 3,972 Right-of-use assets obtained in exchange for new lease liabilities $ 497 $ 541 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of March 31, 2022 and December 31, 2021: March 31, December 31, Weighted-average remaining lease term, years 5.2 5.2 Weighted-average discount rate, % 5.6 % 5.5 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of March 31, 2022, the Company had non-cancelable purchase commitments of $227.1 million, of which $194.5 million are expected to be paid within the year ending December 31, 2022. Legal Proceedings The Company is currently involved in various legal proceedings. A class action lawsuit was filed against the Company, on June 5, 2019, in the Circuit Court of Cook County, Illinois, Chancery Division, captioned Corey Heard, individually and on behalf of all others similarly situated v. Omnicell, Inc., Case No. 2019-CH-06817 (the “Heard Action”). The complaint seeks class certification, monetary damages in the form of statutory damages for willful and/or reckless or, in the alternative, negligent violation of the Illinois Biometric Information Privacy Act (“BIPA”), and certain declaratory, injunctive, and other relief based on causes of action directed to allegations of violation of BIPA by the Company. The complaint was served on the Company on June 13, 2019. On July 31, 2019, the Company filed a motion to stay or consolidate the case with the action Yana Mazya, et al. v. Northwestern Lake Forest Hospital, et al., Case No. 2018-CH-07161, pending in the Circuit Court of Cook County, Illinois, Chancery Division (the “Mazya Action”). The Court subsequently, on October 10, 2019, denied the motion, without prejudice, as being moot in view of the dismissal of the claims against the Company in the Mazya Action. The Company filed a motion to dismiss the complaint in the Heard Action on October 31, 2019. The hearing on the Company’s motion to dismiss was held on September 2, 2020. The Court ruled from the bench and dismissed the complaint without prejudice giving plaintiff leave to file an amended complaint by September 30, 2020. Plaintiff filed an amended complaint on September 30, 2020 and the Company subsequently filed a motion to dismiss the amended complaint on October 28, 2020, which was fully briefed, but the Court had not heard oral argument on the motion. The parties entered into a settlement agreement on January 25, 2022. On February 1, 2022, the Court granted preliminary approval of the settlement. The Court has scheduled a status conference for June 1, 2022. Subject to final approval of the settlement, the Company intends to defend the lawsuit vigorously. On December 21, 2020, Becton, Dickinson and Company (“BD”) filed a complaint against the Company in the United States District Court for the Middle District of North Carolina, asserting claims of misappropriation under the Defend Trade Secrets Act, misappropriation under the North Carolina Trade Secrets Protection Act, unfair competition, and unfair/deceptive trade practices in violation of North Carolina law (the “BD Complaint”). This action (the “BD Action”) was commenced in relation to another action brought by BD, in the same Court (the “Related Matter”) against a former BD employee who is also a former Company employee (the “Former Employee”) alleging that the Former Employee had violated the Former Employee’s legal obligations to BD regarding BD’s confidential and trade secret information when the Former Employee allegedly downloaded certain documents from BD’s information technology system following the end of the Former Employee’s employment with BD. In connection with the Related Matter, BD, the Former Employee, and the Company entered into a protocol with the purpose of facilitating the return to BD of any BD documents that may have been resident, as a result of the Former Employee’s actions, on any devices belonging to the Former Employee or the Company. The BD Complaint seeks injunctive relief and monetary damages in the form of compensatory, punitive, and exemplary damages, attorneys’ fees and costs, and pre-judgment and post-judgment interest. On March 8, 2022, the parties entered into a confidential settlement agreement. Omnicell is currently in the process of effectuating certain obligations under the agreement prior to dismissal of the BD Complaint. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with the legal proceedings described above based on its belief that any potential material loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time or is not deemed material. The Company believes that it has valid defenses with respect to these legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of any of these legal proceedings or because of the diversion of management’s attention and the creation of significant expenses.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 26.4% and 26.7% for the three months ended March 31, 2022 and 2021, respectively. The Company has executed various global operational centralization activities and legal entity rationalization in recent years. The Company did not recognize any gains or losses from such activities during the three months ended March 31, 2022 and 2021. The Company recognized a discrete tax benefit related to equity compensation in the amount of $4.4 million and $4.1 million for the three months ended March 31, 2022 and 2021, respectively. The 2022 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and Global Intangible Low-Taxed Income tax inclusion, partially offset by the favorable impact of research and development credits and a foreign derived intangible income (“FDII”) benefit deduction. The 2021 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and non-deductible expenses, partially offset by the favorable impact of research and development credits and a FDII benefit deduction. On March 11, 2021, the President of the United States signed into law the “American Rescue Plan Act of 2021” (the “ARP Act”), which provides additional economic stimulus and tax credits, including the expansion and modification of the employee retention tax credit enacted by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and the refundable tax credits for COVID-related paid sick and family leave enacted by the Family First Act. The ARP Act further expands the “covered employees” definition for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, used in determining the limitation on the deduction for excessive employee remuneration rules to be applicable for taxable years beginning after December 31, 2026. The provisions of the ARP Act did not have a material impact on the Company’s income taxes. As of March 31, 2022 and December 31, 2021, the Company had gross unrecognized tax benefits of $9.3 million and $9.0 million, respectively. It is the Company’s policy to classify accrued interest and penalties as part of unrecognized tax benefits, but to record interest and penalties in interest and other income (expense), net in the Condensed Consolidated Statements of Operations. As of both March 31, 2022 and December 31, 2021, the amount of accrued interest and penalties was $0.6 million. The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, Netherlands, and the United Kingdom. With few exceptions, as of March 31, 2022, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2018, 2017, and 2017, respectively. Although the Company believes it has adequately provided for uncertain tax positions, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	3 Months Ended
Employee Benefits and Share-Based Compensation	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock-Based Plans For a detailed explanation of the Company’s stock plans, refer to Note 14, Employee Benefits and Share-Based Compensation , of the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 25, 2022. Share-Based Compensation Expense The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Cost of product and service revenues $ 2,244 $ 1,937 Research and development 2,264 1,700 Selling, general, and administrative 11,700 8,135 Total share-based compensation expense $ 16,208 $ 11,772 Employee Stock Purchase Plan (“ESPP”) The following assumptions were used to value shares under the ESPP for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 Expected life, years 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 28.8% - 45.6% 27.4% - 53.5% Risk-free interest rate, % 0.1% - 1.5% 0.1% - 2.6% Dividend yield, % — % — % For the three months ended March 31, 2022 and 2021, employees purchased approximately 175,000 and 156,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $66.81 and $59.75, respectively. As of March 31, 2022, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $3.6 million and is expected to be recognized over a weighted-average period of 1.4 years. Stock Options The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the three months ended March 31, 2021. There were no stock options granted during the three months ended March 31, 2022. Three Months Ended March 31, 2021 Expected life, years 4.9 Expected volatility, % 30.1 % Risk-free interest rate, % 0.6 % Estimated forfeiture rate, % 7.9 % Dividend yield, % — % The following table summarizes the stock option activity during the three months ended March 31, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 2,954 $ 67.35 6.9 $ 334,119 Granted — — Exercised (141) 51.47 Expired (1) 68.74 Forfeited (33) 80.32 Outstanding at March 31, 2022 2,779 $ 68.00 6.8 $ 171,505 Exercisable at March 31, 2022 1,699 $ 58.65 6.0 $ 120,394 Vested and expected to vest at March 31, 2022 and thereafter 2,683 $ 67.36 6.7 $ 167,177 The weighted-average fair value per share of options granted during the three months ended March 31, 2021 was $33.89. The intrinsic value of options exercised during the three months ended March 31, 2022 and 2021 was $12.7 million and $14.0 million, respectively. As of March 31, 2022, total unrecognized compensation cost related to unvested stock options was $28.4 million, which is expected to be recognized over a weighted-average vesting period of 2.0 years. Restricted Stock Units (“RSUs”) The following table summarizes the RSU activity under the 2009 Plan during the three months ended March 31, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 763 $ 119.93 1.6 $ 137,696 Granted (Awarded) 150 147.90 Vested (Released) (43) 84.74 Forfeited (26) 119.49 Outstanding and unvested at March 31, 2022 844 $ 126.70 1.6 $ 109,317 As of March 31, 2022, total unrecognized compensation cost related to RSUs was $85.5 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.0 years. Restricted Stock Awards (“RSAs”) The following table summarizes the RSA activity under the 2009 Plan during the three months ended March 31, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 11 $ 137.36 Granted (Awarded) — — Vested (Released) — — Outstanding and unvested at March 31, 2022 11 $ 137.36 As of March 31, 2022, total unrecognized compensation cost related to RSAs was $0.2 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.2 years. Performance-Based Stock Unit Awards (“PSUs”) The following table summarizes the PSU activity under the 2009 Plan during the three months ended March 31, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 144 $ 118.71 Granted 75 156.82 Additional granted based on performance achievement 51 156.79 Vested (57) 119.09 Forfeited (1) 178.81 Outstanding and unvested at March 31, 2022 212 $ 141.05 As of March 31, 2022, total unrecognized compensation cost related to PSUs was approximately $13.7 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.5 years. Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of March 31, 2022: Number of Shares (In thousands) Share options outstanding 2,779 Non-vested restricted stock awards 1,067 Shares authorized for future issuance 1,154 ESPP shares available for future issuance 744 Total shares reserved for future issuance 5,744 Stock Repurchase Programs On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). As of March 31, 2022, the 2014 Repurchase Program was completed, and the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time.

Restructuring Expenses

Restructuring Expenses	3 Months Ended
Restructuring Expenses	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring Expenses	Restructuring Expenses During 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the industry vision of the Autonomous Pharmacy. In the first quarter of 2021, the Company continued its organizational realignment initiative, incurring $2.0 million of employee severance costs and related expenses. During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives, in order to enhance and streamline certain engineering functions for its domestic operations, and to realign its international sales organization to better serve its customers in various international markets. During the three months ended March 31, 2022, the restructuring plans incurred $3.5 million of employee severance costs and related expenses. As of March 31, 2022 the unpaid balance related to these restructuring plans was $1.8 million. The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Cost of product and service revenues $ 156 $ 389 Research and development 1,594 105 Selling, general, and administrative 1,777 1,526 Total restructuring expense $ 3,527 $ 2,020

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn May 4, 2022, the Company determined that certain of its information technology systems were affected by ransomware impacting certain internal systems. There is an impact on certain of the Company’s products and services, as well as certain of its internal systems. Upon detecting the security event, the Company took immediate steps designed to contain the incident and implement its business continuity plans to restore and support continued operations. The Company has notified appropriate law enforcement authorities. The Company is also working closely with cybersecurity experts and legal counsel. The Company is in the early stages of its investigation and assessment of the security event and cannot determine, at this time, the extent of the impact from such event on our business, results of operations or financial condition or whether such impact will have a material adverse effect.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of March 31, 2022 and December 31, 2021, and the results of operations, comprehensive income, and cash flows for the three months ended March 31, 2022 and 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 25, 2022, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations, comprehensive income, and cash flows for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the year ending December 31, 2022, or for any future period.
Principles of Consolidation	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On January 10, 2022, the Company completed its acquisition of Hub and Spoke Innovations Limited (“Hub and Spoke Innovations”). The Condensed Consolidated Financial Statements include the results of operations of this recently acquired company, commencing as of the acquisition date. The significant accounting policies of the acquired business have been aligned to conform to the accounting policies of Omnicell.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of March 31, 2022, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.
Segment Reporting	Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.
Recently Adopted and Issued Authoritative Guidance	Recently Adopted Authoritative Guidance In August 2020, the Financial Accounting Standards Board (“FASB“) issued Accounting Standards Update (“ASU“) 2020-06 Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) . The update simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU 2020-06 also requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method is no longer permitted for convertible instruments. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2022, using the modified retrospective method of transition. Upon adoption of ASU 2020-06, the previously separated equity component and associated debt issuance costs for the Company’s outstanding convertible senior notes were reclassified to the liability component, thereby eliminating the subsequent amortization of the debt discount as interest expense. In addition, the Company derecognized the deferred tax liability related to the equity component. In December 2021, the Company made an irrevocable election under the indenture to require the principal portion of the Company’s convertible senior notes to be settled in cash and any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion. Following the irrevocable election, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. The Company’s adoption of the update impacted the Condensed Consolidated Balance Sheets at the beginning of the period of adoption as follows: January 1, 2022 Pre-ASU 2020-06 Balances ASU 2020-06 Adoption Impact Post-ASU 2020-06 Balances (In thousands) Long-term deferred tax assets $ 15,883 $ (452) $ 15,431 Convertible senior notes, net 488,152 75,353 563,505 Long-term deferred tax liabilities 51,705 (19,572) 32,133 Additional paid-in capital 1,024,580 (72,742) 951,838 Retained earnings 368,571 16,509 385,080 Adoption of the update did not have an impact on the Company’s Condensed Consolidated Statements of Operations or Condensed Consolidated Statements of Cash Flows as of January 1, 2022. Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes. Recently Issued Authoritative Guidance In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The guidance will be applied prospectively to acquisitions occurring on or after the effective date. ASU 2021-08 will be effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company is currently evaluating the impact ASU 2021-08 will have on its Condensed Consolidated Financial Statements. No other recently issued and effective authoritative guidance is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.
Business Combinations	The Company accounted for its acquisitions in accordance with ASC 805, Business Combinations . The tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the respective acquisition dates. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual or legal criterion or the separability criterion, each as set forth in the accounting guidance. The preliminary fair values reflect management’s best estimates based on information available at the respective acquisition dates and may change as additional information is received over the measurement period, which will end no later than one year from the respective acquisition date. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company’s Condensed Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions. The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization.
Revenue Recognition	Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements with multi-year co-development plans. Solutions in this category include, but are not limited to, XT Series automated dispensing systems, the XR2 Automated Central Pharmacy System, and IV compounding automation solutions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, and are designed to improve patient engagement and adherence to prescriptions. SaaS, subscription software, and technology-enabled services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth inclusive of FDS Amplicare and MarkeTouch Media, 340B solutions, ReCept management services, and services associated with Omnicell One™, Central Pharmacy Dispensing Services, including the XR2 Automated Central Pharmacy System, and Central Pharmacy Compounding Services, including IV compounding automation solutions. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service
Net Income (Loss) Per Share	Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 10, Convertible Senior Notes (pre-ASU 2020-06 adoption). For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1 2022, the Company is required to apply the if-converted method for calculating the dilutive impact of the convertible senior notes. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share.
Fair Value Hierarchy	The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period.
Convertible Debt	Prior to the adoption of ASU 2020-06, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner.Upon adoption of ASU 2020-06, effective January 1, 2022, the Notes are no longer separated into liability and equity components, and are accounted for as a single liability measured at its amortized cost.
Commitments and Contingencies	As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with the legal proceedings described above based on its belief that any potential material loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time or is not deemed material. The Company believes that it has valid defenses with respect to these legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of any of these legal proceedings or because of the diversion of management’s attention and the creation of significant expenses.

Business Combinations and Asset

Business Combinations and Asset Acquisitions (Policies)	3 Months Ended
Business Combinations and Asset Acquisitions (Policies)	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combinations	The Company accounted for its acquisitions in accordance with ASC 805, Business Combinations . The tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the respective acquisition dates. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual or legal criterion or the separability criterion, each as set forth in the accounting guidance. The preliminary fair values reflect management’s best estimates based on information available at the respective acquisition dates and may change as additional information is received over the measurement period, which will end no later than one year from the respective acquisition date. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company’s Condensed Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions. The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization.

Accounting Policies (Tables)

Accounting Policies (Tables)	3 Months Ended
Accounting Policies (Tables)	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Adoption Impacts from ASU 2020-06	The Company’s adoption of the update impacted the Condensed Consolidated Balance Sheets at the beginning of the period of adoption as follows: January 1, 2022 Pre-ASU 2020-06 Balances ASU 2020-06 Adoption Impact Post-ASU 2020-06 Balances (In thousands) Long-term deferred tax assets $ 15,883 $ (452) $ 15,431 Convertible senior notes, net 488,152 75,353 563,505 Long-term deferred tax liabilities 51,705 (19,572) 32,133 Additional paid-in capital 1,024,580 (72,742) 951,838 Retained earnings 368,571 16,509 385,080

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
Business Combinations (Tables)	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed by the Company	The following tables represent the preliminary allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred: FDS Amplicare (1) ReCept (Preliminary) (2) MarkeTouch Media (In thousands) Purchase price transferred: Base purchase price $ 177,000 $ 100,000 $ 82,000 Add: Closing cash 465 6,664 191 Add: Net working capital adjustment 1,654 (2,296) 448 Less: Assumed indebtedness (653) (1,902) (13) Total purchase price transferred $ 178,466 $ 102,466 $ 82,626 FDS Amplicare (Preliminary) (1) ReCept (Preliminary) (2) MarkeTouch Media Fair value of assets acquired and liabilities assumed: Cash and cash equivalents $ 465 $ — $ 237 Accounts receivable and unbilled receivables 5,330 2,383 2,302 Prepaid expenses 506 192 96 Other current assets 45 13,955 — Total current assets 6,346 16,530 2,635 Property and equipment 444 172 177 Operating lease right-of-use assets 2,252 773 602 Goodwill 117,374 81,588 42,530 Intangible assets 70,000 28,100 38,000 Other long-term assets 51 200 2,850 Total assets 196,467 127,363 86,794 Accounts payable 950 219 473 Accrued compensation 1,312 1,756 — Accrued liabilities 1,396 18,499 292 Deferred revenues 1,916 222 347 Long-term deferred tax liabilities 11,377 3,587 — Long-term operating lease liabilities 920 614 206 Other long-term liabilities 130 — 2,850 Total liabilities 18,001 24,897 4,168 Total purchase price $ 178,466 $ 102,466 $ 82,626 Total purchase price, net of cash acquired $ 178,001 $ 95,897 $ 82,389 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. (2) Closing cash is included in other current assets due to its restrictive nature as cash held for customers.
Summary of Identifiable Intangible Assets Acquired	The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: FDS Amplicare (1) ReCept MarkeTouch Media Fair value Useful life Fair value Useful life Fair value Useful life (In thousands, except for years) Customer relationships $ 59,900 23 $ 28,100 23 $ 34,100 26 Acquired technology 7,700 5 - 7 — — 2,100 4 Backlog — — — — 1,800 2 Trade names 2,400 5 — — — — Total purchased intangible assets $ 70,000 $ 28,100 $ 38,000 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships.
Pro Forma Financial Information	Three Months Ended March 31, 2021 (In thousands) Pro forma revenues $ 268,921 Pro forma net income $ 13,066

Revenues (Tables)

Revenues (Tables)	3 Months Ended
Revenues (Tables)	Mar. 31, 2022
Revenue Recognition [Abstract]
Summary of Revenue Recognition for Revenue Categories	The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service
Disaggregation of Revenues by Revenue Type	The following table summarizes the Company’s revenues disaggregated by revenue type for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Connected devices, software licenses, and other $ 208,078 $ 159,718 Technical services 49,169 50,860 Consumables 17,797 18,407 SaaS, subscription software, and technology-enabled services 43,784 22,858 Total revenues $ 318,828 $ 251,843
Disaggregation of Revenues by Geographical Location	The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) United States $ 287,577 $ 224,276 Rest of world (1) 31,251 27,567 Total revenues $ 318,828 $ 251,843 _________________________________________________ (1) No individual country represented more than 10% of total revenues.
Contract Asset and Liabilities	The following table reflects the Company’s contract assets and contract liabilities: March 31, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 17,348 $ 17,208 Long-term unbilled receivables, net (2) 16,316 18,084 Total contract assets $ 33,664 $ 35,292 Short-term deferred revenues, net $ 127,998 $ 112,196 Long-term deferred revenues 24,037 20,194 Total contract liabilities $ 152,035 $ 132,390 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets.

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
Net Income Per Share (Tables)	Mar. 31, 2022
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The basic and diluted net income per share calculations for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended March 31, 2022 2021 (In thousands, except per share data) Net income $ 8,213 $ 14,127 Weighted-average shares outstanding – basic 44,249 42,962 Effect of dilutive securities from stock award plans 1,646 1,980 Effect of convertible senior notes 1,918 1,425 Effect of warrants 105 — Weighted-average shares outstanding – diluted 47,918 46,367 Net income per share – basic $ 0.19 $ 0.33 Net income per share – diluted $ 0.17 $ 0.30 Anti-dilutive weighted-average shares related to stock award plans 336 287 Anti-dilutive weighted-average shares related to convertible senior notes and warrants — 5,908

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
Balance Sheet Components (Tables)	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance sheet details as of March 31, 2022 and December 31, 2021 are presented in the tables below: March 31, December 31, (In thousands) Inventories: Raw materials $ 60,238 $ 48,215 Work in process 9,483 11,009 Finished goods 67,335 60,700 Total inventories $ 137,056 $ 119,924 Other current assets: Funds held for customers, including restricted cash (1) $ 38,426 $ 20,405 Net investment in sales-type leases, current portion 11,103 10,665 Prepaid income taxes 5,265 6,656 Other current assets 4,049 10,608 Total other current assets $ 58,843 $ 48,334 Other long-term assets: Capitalized software, net $ 94,108 $ 96,995 Unbilled receivables, net 16,316 18,084 Deferred debt issuance costs 2,882 3,156 Other long-term assets 8,811 9,284 Total other long-term assets $ 122,117 $ 127,519 Accrued liabilities: Operating lease liabilities, current portion $ 11,809 $ 12,947 Customer fund liabilities 38,426 31,727 Advance payments from customers 10,337 8,191 Rebate liabilities 40,344 44,644 Group purchasing organization fees 6,503 7,115 Taxes payable 5,487 3,771 Other accrued liabilities 26,923 24,772 Total accrued liabilities $ 139,829 $ 133,167 _________________________________________________ (1) Includes restricted cash of $23.4 million and $6.6 million as of March 31, 2022 and December 31, 2021, respectively.
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Beginning balance $ (8,407) $ (5,522) Other comprehensive loss (2,555) (621) Ending balance $ (10,962) $ (6,143)

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Balances	The following table represents the property and equipment balances as of March 31, 2022 and December 31, 2021: March 31, December 31, (In thousands) Equipment $ 90,930 $ 89,272 Furniture and fixtures 7,432 7,580 Leasehold improvements 20,913 20,623 Software 67,795 60,856 Construction in progress 16,217 14,757 Property and equipment, gross 203,287 193,088 Accumulated depreciation and amortization (126,225) (121,947) Total property and equipment, net $ 77,062 $ 71,141
Summary of Geographic Information for Property and Equipment, Net	The following table summarizes the geographic information for property and equipment, net, as of March 31, 2022 and December 31, 2021: March 31, December 31, (In thousands) United States $ 72,803 $ 66,788 Rest of world (1) 4,259 4,353 Total property and equipment, net $ 77,062 $ 71,141 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
Goodwill and Intangible Assets (Tables)	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following table represents changes in the carrying amount of goodwill: December 31, Additions (1) Foreign currency exchange rate fluctuations March 31, (In thousands) Goodwill $ 738,900 2,549 (1,023) $ 740,426 _________________________________________________ (1) Refer to Note 2, Business Combinations, for further information.
Carrying Amounts and Useful Lives of Intangible Assets	The carrying amounts and useful lives of intangible assets as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 311,089 $ (83,571) $ (1,106) $ 226,412 4 - 30 Acquired technology 92,066 (55,492) — 36,574 4 - 20 Backlog 1,800 (225) — 1,575 2 Trade names 9,200 (5,848) — 3,352 5 - 12 Patents 2,430 (1,216) — 1,214 2 - 20 Non-compete agreements 600 (300) — 300 3 Total intangibles assets, net $ 417,185 $ (146,652) $ (1,106) $ 269,427 December 31, 2021 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 309,989 $ (78,093) $ (933) $ 230,963 10 - 30 Acquired technology 95,466 (55,859) 6 39,613 4 - 20 Backlog 1,800 — — 1,800 2 Trade names 9,200 (5,600) 14 3,614 5 - 12 Patents 2,462 (1,186) — 1,276 2 - 20 Non-compete agreements 600 (250) — 350 3 Total intangibles assets, net $ 419,517 $ (140,988) $ (913) $ 277,616 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to the write-off of certain fully amortized intangible assets, partially offset by additions of intangible assets in connection with the Hub and Spoke Innovations acquisition.
Estimated Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for amortizable intangible assets were as follows: March 31, (In thousands) Remaining nine months of 2022 $ 26,204 2023 31,594 2024 23,139 2025 21,086 2026 18,099 Thereafter 149,305 Total $ 269,427

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
Convertible Senior Notes (Tables)	Mar. 31, 2022
Debt Disclosure [Abstract]
Convertible Debt Balances	The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021: March 31, 2022 (2) December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount — (77,136) Unamortized debt issuance costs (10,731) (9,712) Convertible senior notes, liability component (1) $ 564,269 $ 488,152 Convertible senior notes, equity component $ — $ 72,732 _________________________________________________ (1) Classified as a current liability as of both March 31, 2022 and December 31, 2021 in the Condensed Consolidated Balance Sheets. (2) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022.
Summary of Components of Interest Expense	The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 (1) 2021 (In thousands) Contractual coupon interest $ 359 $ 359 Amortization of discount $ — $ 4,571 Amortization of debt issuance costs $ 764 $ 575 _________________________________________________ (1) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022.

Lessor Leases (Tables)

Lessor Leases (Tables)	3 Months Ended
Lessor Leases (Tables)	Mar. 31, 2022
Leases [Abstract]
Income Recognized from Sales-Type Leases	The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Sales-type lease revenues $ 6,505 $ 5,963 Cost of sales-type lease revenues (3,078) (2,366) Selling profit on sales-type lease revenues $ 3,427 $ 3,597
Components of Sales-Type Lease Receivables	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2022 and December 31, 2021: March 31, December 31, (In thousands) Net minimum lease payments to be received $ 32,690 $ 31,444 Less: Unearned interest income portion (2,536) (2,388) Net investment in sales-type leases 30,154 29,056 Less: Current portion (1) (11,103) (10,665) Long-term investment in sales-type leases, net $ 19,051 $ 18,391 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases	The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2022 $ 9,024 2023 9,301 2024 6,300 2025 4,365 2026 1,972 Thereafter 1,728 Total future minimum sales-type lease payments 32,690 Present value adjustment (2,536) Total net investment in sales-type leases $ 30,154
Income Recognized from Operating Leases	The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Rental income $ 2,472 $ 2,611

Lessee Leases (Tables)

Lessee Leases (Tables)	3 Months Ended
Lessee Leases (Tables)	Mar. 31, 2022
Leases [Abstract]
Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities	The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2022 $ 11,244 2023 11,459 2024 9,859 2025 6,909 2026 6,457 Thereafter 10,882 Total operating lease payments 56,810 Present value adjustment (7,728) Total operating lease liabilities (1) $ 49,082 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $11.8 million and $37.3 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities
Supplemental Cash Flow Information Related to Operating Leases	The following table summarizes supplemental cash flow information related to the Company’s operating leases for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 4,193 $ 3,972 Right-of-use assets obtained in exchange for new lease liabilities $ 497 $ 541
Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate	The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of March 31, 2022 and December 31, 2021: March 31, December 31, Weighted-average remaining lease term, years 5.2 5.2 Weighted-average discount rate, % 5.6 % 5.5 %

Employee Benefits and Share-B_2

Employee Benefits and Share-Based Compensation (Tables)	3 Months Ended
Employee Benefits and Share-Based Compensation (Tables)	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Expense	The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Cost of product and service revenues $ 2,244 $ 1,937 Research and development 2,264 1,700 Selling, general, and administrative 11,700 8,135 Total share-based compensation expense $ 16,208 $ 11,772
Assumptions Used to Value ESPP Shares	The following assumptions were used to value shares under the ESPP for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 Expected life, years 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 28.8% - 45.6% 27.4% - 53.5% Risk-free interest rate, % 0.1% - 1.5% 0.1% - 2.6% Dividend yield, % — % — %
Assumptions Used to Value Stock Options Granted	The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the three months ended March 31, 2021. There were no stock options granted during the three months ended March 31, 2022. Three Months Ended March 31, 2021 Expected life, years 4.9 Expected volatility, % 30.1 % Risk-free interest rate, % 0.6 % Estimated forfeiture rate, % 7.9 % Dividend yield, % — %
Summary of Share Option Activity	The following table summarizes the stock option activity during the three months ended March 31, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 2,954 $ 67.35 6.9 $ 334,119 Granted — — Exercised (141) 51.47 Expired (1) 68.74 Forfeited (33) 80.32 Outstanding at March 31, 2022 2,779 $ 68.00 6.8 $ 171,505 Exercisable at March 31, 2022 1,699 $ 58.65 6.0 $ 120,394 Vested and expected to vest at March 31, 2022 and thereafter 2,683 $ 67.36 6.7 $ 167,177
Summary of Restricted Stock Unit Activity	The following table summarizes the RSU activity under the 2009 Plan during the three months ended March 31, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 763 $ 119.93 1.6 $ 137,696 Granted (Awarded) 150 147.90 Vested (Released) (43) 84.74 Forfeited (26) 119.49 Outstanding and unvested at March 31, 2022 844 $ 126.70 1.6 $ 109,317
Summary of Restricted Stock Awards Activity	The following table summarizes the RSA activity under the 2009 Plan during the three months ended March 31, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 11 $ 137.36 Granted (Awarded) — — Vested (Released) — — Outstanding and unvested at March 31, 2022 11 $ 137.36
Summary of Performance-Based Restricted Stock Activity	The following table summarizes the PSU activity under the 2009 Plan during the three months ended March 31, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 144 $ 118.71 Granted 75 156.82 Additional granted based on performance achievement 51 156.79 Vested (57) 119.09 Forfeited (1) 178.81 Outstanding and unvested at March 31, 2022 212 $ 141.05
Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of March 31, 2022: Number of Shares (In thousands) Share options outstanding 2,779 Non-vested restricted stock awards 1,067 Shares authorized for future issuance 1,154 ESPP shares available for future issuance 744 Total shares reserved for future issuance 5,744

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	3 Months Ended
Restructuring Expenses (Tables)	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations	The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (In thousands) Cost of product and service revenues $ 156 $ 389 Research and development 1,594 105 Selling, general, and administrative 1,777 1,526 Total restructuring expense $ 3,527 $ 2,020

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies - Narrative (Details) - segment	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Number of operating segments	1
Number of reportable segments	1
Accounting Standards Update [Extensible Enumeration]		Accounting Standards Update 2020-06 [Member]

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Schedule of Adoption Impacts from ASU 2020-06 (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Line Items]
Long-term deferred tax assets	$ 16,054	$ 15,883
Convertible senior notes, net	564,269	488,152
Long-term deferred tax liabilities	28,173	51,705
Additional paid-in capital	982,675	1,024,580
Retained earnings	$ 393,293	368,571
ASU 2020-06 Adoption Impact
Accounting Policies [Line Items]
Long-term deferred tax assets		(452)
Convertible senior notes, net		75,353
Long-term deferred tax liabilities		(19,572)
Additional paid-in capital		(72,742)
Retained earnings		16,509
Post-ASU 2020-06 Balances
Accounting Policies [Line Items]
Long-term deferred tax assets		15,431
Convertible senior notes, net		563,505
Long-term deferred tax liabilities		32,133
Additional paid-in capital		951,838
Retained earnings		$ 385,080

Business Combinations - Narrati

Business Combinations - Narrative (Details) $ in Thousands, £ in Millions	Jan. 10, 2022USD ($)	Jan. 10, 2022GBP (£)	Dec. 31, 2021USD ($)	Dec. 29, 2021USD ($)	Sep. 09, 2021USD ($)	Mar. 31, 2022USD ($)	Jan. 10, 2022GBP (£)
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill			$ 738,900			$ 740,426
Hub and Spoke Innovations
Acquired Finite-Lived Intangible Assets [Line Items]
Base purchase price	$ 3,400						£ 2.5
Total purchase price transferred	3,400	£ 2.5
Goodwill	2,500						1.9
Intangible assets	$ 1,100						£ 0.8
MarkeTouch Media, LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Base purchase price			82,000
Total purchase price transferred			82,626
Goodwill			42,530
Intangible assets			38,000
Goodwill expected to be deductible for tax purposes			$ 42,500
MarkeTouch Media, LLC \| Discount Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets			0.115
MarkeTouch Media, LLC \| Acquired Technology \| Royalty Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets			0.100
ReCept Holdings, Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Base purchase price				$ 100,000
Total purchase price transferred				102,466
Goodwill				81,588
Intangible assets				28,100
Goodwill expected to be deductible for tax purposes				$ 0
ReCept Holdings, Inc. \| Discount Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets				0.150
FDS Amplicare
Acquired Finite-Lived Intangible Assets [Line Items]
Base purchase price					$ 177,000
Total purchase price transferred					178,466
Goodwill					117,374
Intangible assets					70,000
Goodwill expected to be deductible for tax purposes					$ 0
FDS Amplicare \| Discount Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets					0.130
FDS Amplicare \| Acquired Technology \| Royalty Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets					0.100
FDS Amplicare \| Trade Names \| Royalty Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets					0.020

Business Combinations - Summary

Business Combinations - Summary of Preliminary Purchase Price (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 29, 2021	Sep. 09, 2021
FDS Amplicare
Business Acquisition [Line Items]
Base purchase price			$ 177,000
Add: Closing cash			465
Add: Net working capital adjustment			1,654
Less: Assumed indebtedness			(653)
Total purchase price transferred			$ 178,466
ReCept Holdings, Inc.
Business Acquisition [Line Items]
Base purchase price		$ 100,000
Add: Closing cash		6,664
Add: Net working capital adjustment		(2,296)
Less: Assumed indebtedness		(1,902)
Total purchase price transferred		$ 102,466
MarkeTouch Media, LLC
Business Acquisition [Line Items]
Base purchase price	$ 82,000
Add: Closing cash	191
Add: Net working capital adjustment	448
Less: Assumed indebtedness	(13)
Total purchase price transferred	$ 82,626

Business Combinations - Prelimi

Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed by the Company (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Dec. 29, 2021	Sep. 09, 2021
Business Acquisition [Line Items]
Goodwill	$ 738,900	$ 740,426
FDS Amplicare
Business Acquisition [Line Items]
Cash and cash equivalents				$ 465
Accounts receivable and unbilled receivables				5,330
Prepaid expenses				506
Other current assets				45
Total current assets				6,346
Property and equipment				444
Operating lease right-of-use assets				2,252
Goodwill				117,374
Intangible assets				70,000
Other long-term assets				51
Total assets				196,467
Accounts payable				950
Accrued compensation				1,312
Accrued liabilities				1,396
Deferred revenues				1,916
Long-term deferred tax liabilities				11,377
Long-term operating lease liabilities				920
Other long-term liabilities				130
Total liabilities				18,001
Total purchase price				178,466
Total purchase price, net of cash acquired				$ 178,001
Goodwill, purchase accounting adjustments	1,500
Adjustment, accounts receivable and unbilled receivables	1,100
Decrease in deferred tax liability, noncurrent	100
Adjustment, net working capital	100
FDS Amplicare \| Customer relationships
Business Acquisition [Line Items]
Adjustment, intangibles	400
ReCept Holdings, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents			$ 0
Accounts receivable and unbilled receivables			2,383
Prepaid expenses			192
Other current assets			13,955
Total current assets			16,530
Property and equipment			172
Operating lease right-of-use assets			773
Goodwill			81,588
Intangible assets			28,100
Other long-term assets			200
Total assets			127,363
Accounts payable			219
Accrued compensation			1,756
Accrued liabilities			18,499
Deferred revenues			222
Long-term deferred tax liabilities			3,587
Long-term operating lease liabilities			614
Other long-term liabilities			0
Total liabilities			24,897
Total purchase price			102,466
Total purchase price, net of cash acquired			$ 95,897
MarkeTouch Media, LLC
Business Acquisition [Line Items]
Cash and cash equivalents	237
Accounts receivable and unbilled receivables	2,302
Prepaid expenses	96
Other current assets	0
Total current assets	2,635
Property and equipment	177
Operating lease right-of-use assets	602
Goodwill	42,530
Intangible assets	38,000
Other long-term assets	2,850
Total assets	86,794
Accounts payable	473
Accrued compensation	0
Accrued liabilities	292
Deferred revenues	347
Long-term deferred tax liabilities	0
Long-term operating lease liabilities	206
Other long-term liabilities	2,850
Total liabilities	4,168
Total purchase price	82,626
Total purchase price, net of cash acquired	$ 82,389

Business Combinations - Summa_2

Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 29, 2021	Sep. 09, 2021	Oct. 01, 2020	Dec. 31, 2021
FDS Amplicare
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value				$ 70,000
FDS Amplicare \| Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value				$ 59,900
Useful life				23 years
Adjustment, intangibles					$ 400
FDS Amplicare \| Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value				$ 7,700
FDS Amplicare \| Acquired technology \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life			5 years
FDS Amplicare \| Acquired technology \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life			7 years
FDS Amplicare \| Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value				$ 2,400
Useful life				5 years
ReCept Holdings, Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value		$ 28,100
ReCept Holdings, Inc. \| Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value		$ 28,100
Useful life		23 years
MarkeTouch Media, LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 38,000
MarkeTouch Media, LLC \| Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 34,100
Useful life	26 years
MarkeTouch Media, LLC \| Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 2,100
Useful life	4 years
MarkeTouch Media, LLC \| Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 1,800
Useful life	2 years

Business Combinations - Pro For

Business Combinations - Pro Forma Financial Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Business Combination and Asset Acquisition [Abstract]
Pro forma revenues	$ 268,921
Pro forma net income	$ 13,066

Revenues - Narrative (Details)

Revenues - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
Revenues - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue Recognition [Abstract]
Fees to GPOs	$ 4,500	$ 3,400
Short-term deferred revenues, net	127,998		$ 112,196
Deferred cost of sales	20,300		22,400
Deferred revenues recognized	66,600
Short-term deferred revenues, gross			134,600
Long-term deferred revenues	$ 24,037		$ 20,194
Remaining performance obligation, recognition period	10 years

Revenues - Disaggregation of Re

Revenues - Disaggregation of Revenues by Revenue Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from External Customer [Line Items]
Revenues	$ 318,828	$ 251,843
Connected devices, software licenses, and other
Revenue from External Customer [Line Items]
Revenues	208,078	159,718
Technical services
Revenue from External Customer [Line Items]
Revenues	49,169	50,860
Consumables
Revenue from External Customer [Line Items]
Revenues	17,797	18,407
SaaS, subscription software, and technology-enabled services
Revenue from External Customer [Line Items]
Revenues	$ 43,784	$ 22,858

Revenues - Disaggregation of _2

Revenues - Disaggregation of Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from External Customer [Line Items]
Revenues	$ 318,828	$ 251,843
United States
Revenue from External Customer [Line Items]
Revenues	287,577	224,276
Rest of world
Revenue from External Customer [Line Items]
Revenues	$ 31,251	$ 27,567

Revenues - Contract Asset and L

Revenues - Contract Asset and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Revenue Recognition [Abstract]
Short-term unbilled receivables, net	$ 17,348	$ 17,208
Long-term unbilled receivables, net	16,316	18,084
Total contract assets	33,664	35,292
Short-term deferred revenues, net	127,998	112,196
Long-term deferred revenues	24,037	20,194
Total contract liabilities	$ 152,035	$ 132,390

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ 8,213	$ 14,127
Weighted-average shares outstanding – basic (in shares)	44,249	42,962
Weighted-average shares outstanding — diluted (in shares)	47,918	46,367
Net income per share – basic (in dollars per share)	$ 0.19	$ 0.33
Net income per share – diluted (in dollars per share)	$ 0.17	$ 0.30
Restricted Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	1,646	1,980
Anti-dilutive weighted-average shares (in shares)	336	287
Convertible Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	1,918	1,425
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	105	0
Convertible Senior Notes and Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted-average shares (in shares)	0	5,908

Cash and Cash Equivalents and_2

Cash and Cash Equivalents and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 265,008	$ 349,051	$ 548,055
Cash equivalents	224,800	320,200
Convertible Senior Notes \| Convertible Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term debt, fair value	810,500
Long-term debt, current maturities	$ 564,269	$ 488,152

Balance Sheet Components - Bala

Balance Sheet Components - Balance Sheet Components (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Inventories:
Raw materials	$ 60,238	$ 48,215
Work in process	9,483	11,009
Finished goods	67,335	60,700
Total inventories	137,056	119,924
Other current assets:
Funds held for customers, including restricted cash	38,426	20,405
Net investment in sales-type leases, current portion	11,103	10,665
Prepaid income taxes	5,265	6,656
Other current assets	4,049	10,608
Total other current assets	58,843	48,334
Other long-term assets:
Capitalized software, net	94,108	96,995
Unbilled receivables, net	16,316	18,084
Deferred debt issuance costs	2,882	3,156
Other long-term assets	8,811	9,284
Total other long-term assets	$ 122,117	$ 127,519
Accrued liabilities:
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total accrued liabilities	Total accrued liabilities
Operating lease liabilities, current portion	$ 11,809	$ 12,947
Customer fund liabilities	38,426	31,727
Advance payments from customers	10,337	8,191
Rebate liabilities	40,344	44,644
Group purchasing organization fees	6,503	7,115
Taxes payable	5,487	3,771
Other accrued liabilities	26,923	24,772
Total accrued liabilities	139,829	133,167
Cash and Cash Equivalents [Line Items]
Restricted cash	23,353		$ 1,361
Other Current Assets
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 23,400	$ 6,600

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	$ 1,146,689	$ 967,503
Balance at end of period	1,074,741	1,011,011
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	(8,407)	(5,522)
Other comprehensive loss	(2,555)	(621)
Balance at end of period	$ (10,962)	$ (6,143)

Property and Equipment - Proper

Property and Equipment - Property, Plant and Equipment Balances (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 203,287	$ 193,088
Accumulated depreciation and amortization	(126,225)	(121,947)
Total property and equipment, net	77,062	71,141
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	90,930	89,272
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,432	7,580
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,913	20,623
Software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	67,795	60,856
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 16,217	$ 14,757

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 5.3	$ 4.8

Property and Equipment - Summar

Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 77,062	$ 71,141
United States
Property, Plant and Equipment [Line Items]
Property and equipment, net	72,803	66,788
Rest of world
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 4,259	$ 4,353

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Goodwill [Roll Forward]
Balance at beginning of period	$ 738,900
Additions	2,549
Foreign currency exchange rate fluctuations	(1,023)
Balance at end of period	$ 740,426

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 417,185	$ 419,517
Accumulated amortization	(146,652)	(140,988)
Foreign currency exchange rate fluctuations	(1,106)	(913)
Net carrying amount	269,427	277,616
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	311,089	309,989
Accumulated amortization	(83,571)	(78,093)
Foreign currency exchange rate fluctuations	(1,106)	(933)
Net carrying amount	$ 226,412	$ 230,963
Customer relationships \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	4 years	10 years
Customer relationships \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 92,066	$ 95,466
Accumulated amortization	(55,492)	(55,859)
Foreign currency exchange rate fluctuations	0	6
Net carrying amount	$ 36,574	$ 39,613
Acquired technology \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	4 years	4 years
Acquired technology \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,800	$ 1,800
Accumulated amortization	(225)	0
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 1,575	$ 1,800
Useful life	2 years	2 years
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 9,200	$ 9,200
Accumulated amortization	(5,848)	(5,600)
Foreign currency exchange rate fluctuations	0	14
Net carrying amount	$ 3,352	$ 3,614
Trade names \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	5 years	5 years
Trade names \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	12 years	12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,430	$ 2,462
Accumulated amortization	(1,216)	(1,186)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 1,214	$ 1,276
Patents \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	2 years	2 years
Patents \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years
Non-compete agreements
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 600	$ 600
Accumulated amortization	(300)	(250)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 300	$ 350
Useful life	3 years	3 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 9.1	$ 6.3

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining nine months of 2022	$ 26,204
2023	31,594
2024	23,139
2025	21,086
2026	18,099
Thereafter	149,305
Net carrying amount	$ 269,427	$ 277,616

Debt and Credit Agreement (Deta

Debt and Credit Agreement (Details) - Line of Credit	Nov. 15, 2019USD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Sep. 22, 2020
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Minimum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.15%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Maximum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.30%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR
Debt Instrument [Line Items]
Spread on variable interest rate	1.00%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR \| Minimum
Debt Instrument [Line Items]
Spread on variable interest rate	1.25%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR \| Maximum
Debt Instrument [Line Items]
Spread on variable interest rate	2.00%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Federal Funds
Debt Instrument [Line Items]
Spread on variable interest rate	0.50%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR Plus 1.00% \| Minimum
Debt Instrument [Line Items]
Spread on variable interest rate	0.25%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR Plus 1.00% \| Maximum
Debt Instrument [Line Items]
Spread on variable interest rate	1.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Outstanding balance for revolving credit		$ 0	$ 0
Revolving Credit Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Term of debt instrument	5 years
Maximum borrowing capacity	$ 500,000,000
Revolving Credit Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Calendar Quarters Up To and Including March 31, 2021
Debt Instrument [Line Items]
Maximum secured net leverage ratio				3.50
Revolving Credit Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Calendar Quarters After March 31, 2021
Debt Instrument [Line Items]
Maximum secured net leverage ratio				3
Incremental Loan Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity	250,000,000
Letter of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity	15,000,000
Swing Line Loan \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25,000,000

Convertible Senior Notes - Narr

Convertible Senior Notes - Narrative (Details)	Sep. 25, 2020USD ($)day$ / sharesshares	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Debt Instrument [Line Items]
Purchase of convertible note hedge	$ 100,600,000
Proceeds from sale of warrants	51,300,000
Convertible Note Hedge
Debt Instrument [Line Items]
Deferred tax asset related to the convertible note hedge transaction	$ 25,800,000
Convertible Note Hedge Rights
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) \| shares	5,900,000
Strike price (in dollars per share) \| $ / shares	$ 97.32
Warrants
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) \| shares	5,900,000
Strike price (in dollars per share) \| $ / shares	$ 141.56
Convertible Senior Notes
Debt Instrument [Line Items]
Debt instrument, convertible, principal amount of notes, minimum		$ 1,000
Debt instrument, convertible, maximum cash		1,000
Debt instrument, convertible, consideration in excess, amount		1,000
Convertible Senior Notes \| Convertible Debt
Debt Instrument [Line Items]
Interest rate	0.25%
Principal amount	$ 575,000,000	575,000,000	$ 575,000,000
Additional principal amount subject to purchasers' option	75,000,000
Proceeds from issuance of convertible senior notes, net of issuance costs	559,700,000
Debt issuance costs incurred and capitalized	$ 15,300,000
Conversion ratio	0.0102751
Conversion price (in dollars per share) \| $ / shares	$ 97.32
Repurchase price as a percent of principal amount	100.00%
Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes	$ 150,000,000
Carrying value of debt	461,800,000
Equity component of convertible senior notes	$ 72,700,000	$ 0	$ 72,732,000
Effective interest rate	4.18%
Remaining life of debt discount and issuance cost accretion		3 years 6 months
Maximum number of shares issuable upon conversion (in shares) \| shares	5,900,000
Excess principal amount over the if-converted value		$ 190,100,000
Convertible Senior Notes \| Convertible Debt \| Period 1
Debt Instrument [Line Items]
Threshold trading days \| day	20
Threshold consecutive trading days \| day	30
Threshold percentage of stock price trigger	130.00%
Convertible Senior Notes \| Convertible Debt \| Period 2
Debt Instrument [Line Items]
Threshold trading days \| day	5
Threshold consecutive trading days \| day	10
Threshold percentage of stock price trigger	98.00%

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt Balances (Details) - Convertible Debt - Convertible Senior Notes - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Sep. 25, 2020
Liability:
Principal amount	$ 575,000,000	$ 575,000,000	$ 575,000,000
Unamortized discount	0	(77,136,000)
Unamortized debt issuance costs	(10,731,000)	(9,712,000)
Convertible senior notes, liability component	564,269,000	488,152,000
Convertible senior notes, equity component	$ 0	$ 72,732,000	$ 72,700,000

Convertible Senior Notes - Summ

Convertible Senior Notes - Summary of Components of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Amortization of discount	$ 0	$ 4,571
Amortization of debt issuance costs	1,038	849
Convertible Senior Notes \| Convertible Debt
Debt Instrument [Line Items]
Contractual coupon interest	359	359
Amortization of discount	0	4,571
Amortization of debt issuance costs	$ 764	$ 575

Lessor Leases - Narrative (Deta

Lessor Leases - Narrative (Details)	3 Months Ended
Lessor Leases - Narrative (Details)	Mar. 31, 2022
Lease Receivable \| Customer Concentration Risk \| U.S. Government Hospitals
Lessor, Lease, Description [Line Items]
Concentration risk percentage	62.00%
Minimum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	1 year
Term of operating leases	1 year
Maximum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	5 years
Term of operating leases	7 years

Lessor Leases - Income Recogniz

Lessor Leases - Income Recognized from Sales-Type Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Sales-type lease revenues	$ 6,505	$ 5,963
Cost of sales-type lease revenues	(3,078)	(2,366)
Selling profit on sales-type lease revenues	$ 3,427	$ 3,597

Lessor Leases - Components of S

Lessor Leases - Components of Sales-Type Lease Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Net minimum lease payments to be received	$ 32,690	$ 31,444
Less: Unearned interest income portion	(2,536)	(2,388)
Net investment in sales-type leases	30,154	29,056
Less: Current portion	(11,103)	(10,665)
Long-term investment in sales-type leases, net	$ 19,051	$ 18,391

Lessor Leases - Maturity Schedu

Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Remaining nine months of 2022	$ 9,024
2023	9,301
2024	6,300
2025	4,365
2026	1,972
Thereafter	1,728
Net minimum lease payments to be received	32,690	$ 31,444
Present value adjustment	(2,536)	$ (2,388)
Total net investment in sales-type leases	$ 30,154

Lessor Leases - Income Recogn_2

Lessor Leases - Income Recognized from Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Rental income	$ 2,472	$ 2,611

Lessee Leases - Narrative (Deta

Lessee Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 4,100	$ 3,700
Impairment of operating lease right-of-use assets	$ 1,753	$ 0
Minimum
Lessee, Lease, Description [Line Items]
Term of operating leases	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of operating leases	12 years

Lessee Leases - Maturity Schedu

Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Remaining nine months of 2022	$ 11,244
2023	11,459
2024	9,859
2025	6,909
2026	6,457
Thereafter	10,882
Total operating lease payments	56,810
Present value adjustment	(7,728)
Total operating lease liabilities	49,082
Current portion of operating lease liabilities	11,809	$ 12,947
Long-term portion of operating lease liabilities	$ 37,273	$ 39,911
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities

Lessee Leases - Supplemental Ca

Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 4,193	$ 3,972
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 497	$ 541

Lessee Leases - Weighted-Averag

Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term	5 years 2 months 12 days	5 years 2 months 12 days
Weighted-average discount rate	5.60%	5.50%

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable purchase commitments	$ 227.1
Non-cancelable purchase commitments expected to be paid within the year	$ 194.5

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Income Tax Contingency [Line Items]
Annual effective tax rate	26.40%	26.70%
Discrete tax benefit	$ 3,243	$ 1,208
Unrecognized tax benefits	9,300		$ 9,000
Accrued interest and penalties	600		$ 600
Equity Compensation
Income Tax Contingency [Line Items]
Discrete tax benefit	$ 4,400	$ 4,100

Employee Benefits and Share-B_3

Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 16,208	$ 11,772
Cost of product and service revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	2,244	1,937
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	2,264	1,700
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 11,700	$ 8,135

Employee Benefits and Share-B_4

Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares (Details) - ESPP shares available for future issuance - 1997 Plan	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (minimum)	28.80%	27.40%
Expected volatility (maximum)	45.60%	53.50%
Risk-free interest rate (minimum)	0.10%	0.10%
Risk-free interest rate (maximum)	1.50%	2.60%
Dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 months	6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years

Employee Benefits and Share-B_5

Employee Benefits and Share-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Aug. 02, 2016	Nov. 04, 2014
The 2016 Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)			$ 50,000,000
Remaining value of shares authorized for repurchase under stock repurchase programs	$ 2,700,000
2014 Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)				$ 50,000,000
2016 and 2014 Share Repurchase Programs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares repurchased (in shares)	389,300	0
Average price of repurchased shares (in dollars per share)	$ 134.11
Aggregate purchase price of treasury stock	$ 52,200,000
1997 Plan \| ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchased under ESPP (in shares)	175,000	156,000
Weighted-average price of shares purchased (in dollars per share)	$ 66.81	$ 59.75
Unrecognized compensation cost	$ 3,600,000
Weighted average period of compensation cost not yet recognized	1 year 4 months 24 days
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)	0
Weighted-average fair value of options granted (in dollars per share)		$ 33.89
Intrinsic value of options exercised	$ 12,700,000	$ 14,000,000
Unrecognized compensation cost of unvested stock options	$ 28,400,000
2009 Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized	2 years
2009 Plan \| RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized	3 years
Unrecognized compensation cost	$ 85,500,000
2009 Plan \| RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized	2 months 12 days
Unrecognized compensation cost	$ 200,000
2009 Plan \| PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized	1 year 6 months
Unrecognized compensation cost	$ 13,700,000

Employee Benefits and Share-B_6

Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) - Stock Options	3 Months Ended
	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years 10 months 24 days
Expected volatility	30.10%
Risk-free interest rate	0.60%
Estimated forfeiture rate	7.90%
Dividend yield	0.00%

Employee Benefits and Share-B_7

Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Shares
Outstanding at beginning of period (in shares)	2,954,000
Granted (in shares)	0
Exercised (in shares)	(141,000)
Expired (in shares)	(1,000)
Forfeited (in shares)	(33,000)
Outstanding at end of period (in shares)	2,779,000	2,954,000
Exercisable at end of period (in shares)	1,699,000
Vested and expected to vest at end of period (in shares)	2,683,000
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 67.35
Granted (in dollars per share)	0
Exercised (in dollars per share)	51.47
Expired (in dollars per share)	68.74
Forfeited (in dollars per share)	80.32
Outstanding at end of period (in dollars per share)	68	$ 67.35
Exercisable at end of period (in dollars per share)	58.65
Vested and expected to vest at end of period (in dollars per share)	$ 67.36
Weighted-Average Remaining Years
Outstanding	6 years 9 months 18 days	6 years 10 months 24 days
Exercisable	6 years
Vested and expected to vest	6 years 8 months 12 days
Aggregate Intrinsic Value
Outstanding	$ 171,505	$ 334,119
Exercisable	120,394
Vested and expected to vest	$ 167,177

Employee Benefits and Share-B_8

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - RSUs - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Shares
Outstanding at beginning of period (in shares)	763
Granted (Awarded) (in shares)	150
Vested (Released) (in shares)	(43)
Forfeited (in shares)	(26)
Outstanding and unvested at end of period (in shares)	844	763
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 119.93
Granted (Awarded) (in dollars per share)	147.90
Vested (Released) (in dollars per share)	84.74
Forfeited (in dollars per share)	119.49
Outstanding and unvested at end of period (in dollars per share)	$ 126.70	$ 119.93
Weighted-Average Remaining Years
Outstanding and unvested	1 year 7 months 6 days	1 year 7 months 6 days
Aggregate Intrinsic Value
Outstanding and unvested	$ 109,317	$ 137,696

Employee Benefits and Share-B_9

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) - RSAs - 2009 Plan shares in Thousands	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares) \| shares	11
Granted (Awarded) (in shares) \| shares	0
Vested (Released) (in shares) \| shares	0
Outstanding and unvested at end of period (in shares) \| shares	11
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 137.36
Granted (Awarded) (in dollars per share) \| $ / shares	0
Vested (Released) (in dollars per share) \| $ / shares	0
Outstanding and unvested at end of period (in dollars per share) \| $ / shares	$ 137.36

Employee Benefits and Share-_10

Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) - Performance-Based Restricted Stock - 2009 Plan shares in Thousands	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares) \| shares	144
Granted (Awarded) (in shares) \| shares	75
Additional granted based on performance achievement (in shares) \| shares	51
Vested (Released) (in shares) \| shares	(57)
Forfeited (in shares) \| shares	(1)
Outstanding and unvested at end of period (in shares) \| shares	212
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 118.71
Granted (Awarded) (in dollars per share) \| $ / shares	156.82
Additional granted based on performance achievement (in dollars per share) \| $ / shares	156.79
Vested (Released) (in dollars per share) \| $ / shares	119.09
Forfeited (in dollars per share) \| $ / shares	178.81
Outstanding and unvested at end of period (in dollars per share) \| $ / shares	$ 141.05

Employee Benefits and Share-_11

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Mar. 31, 2022shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	5,744
Share options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	2,779
Non-vested restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	1,067
Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	1,154
ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	744

Restructuring Expenses - Narrat

Restructuring Expenses - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring expenses	$ 3,527	$ 2,020
Unpaid balance related to restructuring plan	$ 1,800

Restructuring Expenses - Total

Restructuring Expenses - Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 3,527	$ 2,020
Cost of product and service revenues
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	156	389
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1,594	105
Selling, general, and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 1,777	$ 1,526